Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-19
2011-07-19
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S350000
Reexamination Certificate
active
07981893
ABSTRACT:
Provided herein are Heteroaryl Compounds having the following structure:wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
REFERENCES:
patent: 3507866 (1970-04-01), Jones et al.
patent: 3567725 (1971-03-01), Grabowski et al.
patent: 4294836 (1981-10-01), Lesher et al.
patent: 4294837 (1981-10-01), Lesher et al.
patent: 4309537 (1982-01-01), Lesher et al.
patent: 4317909 (1982-03-01), Lesher et al.
patent: 4898872 (1990-02-01), Campbell et al.
patent: 4963561 (1990-10-01), Lesher et al.
patent: 5424311 (1995-06-01), Billhardt-Troughton
patent: 5869659 (1999-02-01), Stolle et al.
patent: 6093728 (2000-07-01), McMahon et al.
patent: 6372740 (2002-04-01), Murata et al.
patent: 6566367 (2003-05-01), Bakthavatchalam et al.
patent: 6855723 (2005-02-01), McMahon et al.
patent: 2003/0036652 (2003-02-01), Bakthavatchalam et al.
patent: 2003/0162968 (2003-08-01), Ciriillo et al.
patent: 2006/0004014 (2006-01-01), Hoffmann et al.
patent: 2006/0106022 (2006-05-01), Liu et al.
patent: 2006/0135511 (2006-06-01), Burgey
patent: 2 458 699 (2003-03-01), None
patent: 262 026 (1988-11-01), None
patent: 0 385 850 (1990-09-01), None
patent: 63275582 (1987-05-01), None
patent: 200148882 (2001-02-01), None
patent: 2002167387 (2002-06-01), None
patent: WO 99/16438 (1999-04-01), None
patent: WO 99/28320 (1999-06-01), None
patent: WO 00/73306 (2000-12-01), None
patent: WO 02/048152 (2002-06-01), None
patent: WO 03/032989 (2003-04-01), None
patent: WO 2004/042002 (2004-05-01), None
patent: WO 2004/065378 (2004-08-01), None
patent: WO 2004/076454 (2004-09-01), None
patent: WO 2004/085409 (2004-10-01), None
patent: WO 2005/120511 (2005-12-01), None
patent: WO 2006/001266 (2006-01-01), None
patent: WO 2006/030031 (2006-03-01), None
patent: WO 2006/036883 (2006-04-01), None
patent: WO 2006/045828 (2006-05-01), None
patent: WO 2006/065703 (2006-06-01), None
patent: WO 2006/091737 (2006-08-01), None
patent: WO 2006/108103 (2006-10-01), None
patent: WO 2008/016669 (2008-02-01), None
patent: WO 2010/068483 (2010-06-01), None
Patani et al. “Bioisosterism: A Rational Approach in Drug Design”, 1996, Chemical Reviews, 96, 3147-3176.
Barlin, Gordon. “Purine analogs as amplifiers of phleomycin.VII. Some 1H-imidazo[4,5-b]pyrazines and related compound”. 1982, Australian Journal of Chemistry, 35, 2299-306.(Abstract only).
Jones et al., 1973, “6-Substituted-5-chloro-1,3-dihydro-2H-imidazo(4,5-b)pyrazin-2-ones with hypotensive activity,” J. Med. Chem., vol. 16(5):537-542.
Kazaoka et al., 2003, “Synthesis of 6-substituted 9-benzyl-8-hydroxypurines with potential interferon-indcuing activity,” Chemical & Pharmaceutical Bulletin, vol. 51(5):608-611.
Killday et al., 2001, “Microxine, a new cdc2 kinase inhibitor from the Australian marine sponge Microxina species,” J. of Natural Products, vol. 64(4):525-526.
Beresnev et al., 2000, “Interaction of 5-methoxy-1,2,4-traizines with uras as a new route to 6-azapurines,” Medeleev Commu., vol. 2:58-59.
Bergman et al., 1963, “2-Phenylpurines, their chemical and enzumological reactivity,” J. Chem Org. , pp. 3729-3735.
Chupakhin et al., 2001, “A simple one pot synthesis of condensed 1,2,4-triazines by using the tandem AN-SNipsoand SNH—SNipsoreactions,” J. of Heterocyclic Chemistry, vol. 38(4):901-907.
Cohen. P. 2001, “The role of protein phosphorylation in human health and diesease,” eur. J. Biochem, vol. 268, pp. 5001-5010.
Cohen, P. 2002, “Protein kinases—The major drug targets of the twenty-first century?” Nature Reviews/Drug Discovery, vol. 1, pp. 309-315.
Crofts et al., 1997 “Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by human cytochrome P4501B1,” Carcinogenesis, vol. 18(9):1793-1798.
DATABASE CAPLUS Online Chemical Abstracts Service, Columbus, Ohio, Database Accession No. 1951:49974 (XP-002472261) (1951).
DATABASE CAPLUS Online Chemical Abstracts Service, Columbus, Ohio, Database Accession No. 1978:433195 (XP-002472262) (1978).
DATABASE CAPLUS Online Chemical Abstracts Service, Columbus, Ohio, Database Accession No. 1966:26849 (XP-002472263) (1965).
Dornow et al., 1957, “Synthese von2-Oxy-imidazolo-(5′,4′:2,3)-pyridinen),” Arch Pharm. vol. 290, pp. 20-31 (w/English language abstract).
Dzierba et al., 2004, “Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists,” J of Medicinal Chemistry, vol. 47, pp. 5783-5790.
Fabbro et al., 2002, “Protein kinases as targets for anticancer agents: from inhibitors touseful drugs,” Pharmacology & Therapeutics, vol. 93, pp. 79-98.
Farhadi et al.,2006, “The role of protien kinase C isoforms in modulating injury and repair of the intestinal barrier,” J. Pharm. Exp. Ther. vol. 316, pp. 1-7.
Frandsen et al., 1992, “Reaction of the N2-acetoxy derivative of 2-amino-1-methyl-6-phenylimidazo[4,5,b] pyridine . . . ,” Carcinogenesis, vol. 13(4):629-35.
Georgakis and Younes, 1978, “From rapa nui to rapamycin:targeting PI3K/Akt/mTOR for cancer therapy,” Expert Rev. Anticancer Ther, vol. 6:131-140.
Irie et al., 2005, “Toward the development of new medicinal leads with selectivity for protein kinase C isozymes,” The Chemical Record, vol. 5:185-195.
Itoh etal., 2004, “A novel practical synthesis of C-2-arylpurines,” Advanced Synthesis & Catalysis, vol. 346:1859-1867.
Minehan et al., 2000, “Molecular recognition of DNA by Hoechst Benzimidazoles: Exploring beyond theopyrrole-imidazole-hydroxypyrrole polyamide-pairing code,” Helvitica Chima Acta, vol. 83(9):2197-2213.
Nagashima et al., 2004, “Solution-Phase parallel synthesis of an N-Alkylated dihydropteridinone library from fluorous amino acids,” J of Comb. Chemistry, vol. 6, pp. 942-949.
Park et al., 2000, “A novel mechanism of TRAF signaling revealed by structural and functional analyses of the TRADD-TRAF2 interaction,” Cell, vol. 101, pp. 777-787.
Singh et al., 1994, “Novel cAMP PDE III Inhibitors: Imidazo[4,5-b]pyridin-2(3H)-ones and Thiazolo[4,5-b]pyridin-2(3h)-ones and Their Analogs,” J. Med. Chem, vol. 37(2):248-54.
Sridhar et al., 2000, “Protein Kinasesas Therapeutic Targets,” Pharm. Research, vol. 17(11):1345-53.
Yoneda et al., 1978, “Synthesis of imadazo[4,5-e]-as-triazine (6-Azapurine) Deriviatives,” Chem & Pharm Bulletin, vol. 26(10):3154-60.
Yoneda etal., 1976, “A transformationof 7-azapteridines into 6-azapurines (Imidazo[4,5-e]-as—triazines),” Heterocycles, vol. 4(9):1503-8.
Barlin, 1982, “Purine Analogs as Amplifiers of Phleomycin. VII* Some 1H-Imidazo[4,5-b]pyrazines and Related Compounds,”Australian Journal of Chemistry 35(11):2299-2306.
Albers Ronald J.
Delgado Mederos Maria Mercedes
Harris, III Roy Leonard
Huang Dehua
Lee Branden G.
Jones Day
McDowell Brian
Signal Pharmaceuticals LLC
Wilson James O
LandOfFree
Heteroaryl compounds, compositions thereof, and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl compounds, compositions thereof, and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl compounds, compositions thereof, and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2659025